, Volume 30, Issue 4, pp 620-626
Date: 13 Jan 2004

Effects of protective and conventional mechanical ventilation on pulmonary function and systemic cytokine release after cardiopulmonary bypass

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Objective

To evaluate the effects of protective and conventional ventilation with or without positive end-expiratory pressure (PEEP), on systemic tumor necrosis factor-α, interleukin-6 levels and pulmonary function during open heart surgery.

Design

Prospective, randomized clinical study.

Setting

Single university hospital.

Patients and participants

Forty-four patients undergoing elective coronary artery bypass grafting surgery with cardiopulmonary bypass.

Interventions

Patients ventilated with (1) protective tidal volumes (6 ml/kg, respiratory rate: 15 breaths/min, PEEP 5 cmH2O, n=15) group PV; (2) conventional tidal volumes (10 ml/kg, respiratory rate: 9 breaths/min, PEEP 5 cmH2O, n=14) group CV+PEEP and (3) conventional tidal volumes (10 ml/kg, respiratory rate: 9 breaths/min, n=15) without PEEP, group CV+ZEEP. Various pulmonary parameters, systemic TNF-α and IL-6 levels were determined throughout the study.

Measurements and results

There were no differences among the groups regarding the systemic TNF- α and IL-6 levels. The plateau airway pressures of group PV were lower than those of groups CV+PEEP (p=0.02) and CV+ZEEP (p=0.001) after cardiopulmonary bypass. The shunt fraction of group PV was significantly lower than that of group CV+ZEEP 24 h after surgery (p<0.05). Oxygenation and the alveolar-arterial oxygen difference were better in both PEEP groups than in group CV+ZEEP 24 h after the operation.

Conclusions

We could not find any evidence that protective mechanical ventilation prevents some of the adverse effects of cardiopulmonary bypass on the lung, nor systemic cytokine levels, postoperative pulmonary function or length of hospitalization.

This research is partially supported by Fresenius—Kabi and Aventis Pharma.